Cargando…

Acute Fingolimod Effects on Baroreflex and Cardiovascular Autonomic Control in Multiple Sclerosis

BACKGROUND: Fingolimod, an oral drug used in multiple sclerosis (MS) treatment, exerts its action through S1P-receptor engagement. These receptors are also expressed in heart and endothelial cells. The engagement of receptors on the atrial heart myocytes may cause a slowing effect on heart rate (HR)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Racca, Vittorio, Rovaris, Marco, Cavarretta, Rosella, Vaini, Emanuele, Toccafondi, Anastasia, Di Rienzo, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537493/ https://www.ncbi.nlm.nih.gov/pubmed/31205439 http://dx.doi.org/10.1177/1179573519849945

Ejemplares similares

Cardiovascular fingolimod effects on rapid baroreceptor unloading are counterbalanced by baroreflex resetting
por: Hilz, Max J., et al.
Publicado: (2021)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Peripheral Resistance Baroreflex During Incremental Bicycle Ergometer Exercise: Characterization and Correlation With Cardiac Baroreflex
por: Porta, Alberto, et al.
Publicado: (2018)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

An algorithm for the beat-to-beat assessment of cardiac mechanics during sleep on Earth and in microgravity from the seismocardiogram
por: Di Rienzo, Marco, et al.
Publicado: (2017)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Closed-Loop Cardiovascular Interactions and the Baroreflex Cardiac Arm: Modulations Over the 24 h and the Effect of Hypertension
por: Parati, Gianfranco, et al.
Publicado: (2019)

Comparison of Causal and Non-causal Strategies for the Assessment of Baroreflex Sensitivity in Predicting Acute Kidney Dysfunction After Coronary Artery Bypass Grafting
por: Bari, Vlasta, et al.
Publicado: (2019)

Modulation of Tregs and iNKT by Fingolimod in Multiple Sclerosis Patients
por: Ferraro, Diana, et al.
Publicado: (2021)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Hypoglycemia Impairs Baroreflex Sensitivity: Implications for Autonomic Control of Cardiovascular Function in Diabetes
por: Haas, Andrea, et al.
Publicado: (2021)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2015)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023)

Information domain analysis of the spontaneous baroreflex during pharmacological challenges
por: Porta, Alberto, et al.
Publicado: (2013)

Acute Thermoregulatory and Cardiovascular Response to Submaximal Exercise in People With Multiple Sclerosis
por: Gervasoni, Elisa, et al.
Publicado: (2022)

Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod
por: Fukai, Ryoko, et al.
Publicado: (2019)

Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients
por: Bianco, Assunta, et al.
Publicado: (2021)

Oxidative Stress Is Differentially Present in Multiple Sclerosis Courses, Early Evident, and Unrelated to Treatment
por: Gironi, Maira, et al.
Publicado: (2014)

Cardiovascular autonomic modulation and baroreflex control in the second trimester of pregnancy: A cross sectional study
por: Corrêa, Mikaela da Silva, et al.
Publicado: (2019)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
por: Marriott, James J.
Publicado: (2011)

Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients
por: Farrokhi, Mehrdad, et al.
Publicado: (2015)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2017)

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
por: Bascuñana, Pablo, et al.
Publicado: (2020)

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021)

Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis
por: Vaheb, Saeed, et al.
Publicado: (2023)

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
por: Murgia, Federica, et al.
Publicado: (2023)

Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis
por: Cohan, Stanley, et al.
Publicado: (2015)

Characterization of the Asymmetry of the Cardiac and Sympathetic Arms of the Baroreflex From Spontaneous Variability During Incremental Head-Up Tilt
por: De Maria, Beatrice, et al.
Publicado: (2019)

The analysis of a reference value for baroreflex sensitivity and cardiovascular autonomic neuropathy prevalence in a Chinese population
por: Tang, Zi-Hui, et al.
Publicado: (2014)

Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
por: Sharma, Sushil, et al.
Publicado: (2011)

Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis
por: Liu, Lei, et al.
Publicado: (2012)

Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)

Patient experience and practice trends in multiple sclerosis – clinical utility of fingolimod
por: Lee, Jong-Mi, et al.
Publicado: (2015)

Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions
por: Muris, Anne-Hilde, et al.
Publicado: (2014)

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod
por: Correale, Jorge, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0s0l2a92d4kpcq9sfn7qasi12l